Sarepta Therapeutics (SRPT) Posts Q1 Loss of 75c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.75), $0.05 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $6.09 million versus the consensus estimate of $3.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Choiceone Financial Services, Inc. (COFS) Misses Q2 EPS by 5c
• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays